

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated August 9, 1985	
1. Central Montana Hospital		3. License number 25-18307-01 is amended in its entirety to read as follows:	
2. 458 Wendell Avenue P. O. Box 580 Lewistown, Montana 59457		4. Expiration date April 30, 1989	
		5. Docket or Reference No. 030-14819	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.	
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 2 curies of each byproduct material authorized in Subitem 6.B.	
C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	C. Any	C. 3 millicuries of each byproduct material authorized in Subitem 6.C.	

8510240593 850830
REG4 LIC30
25-18307-01 PDR

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
25-18307-01

Docket or Reference number
030-14819

Amendment No. 04

D. Iodine-131

D. Any iodine that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State Regulations.

D. 300 millicuries

9. Authorized use

- A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.
- C. In vitro studies.
- D. Treatment of thyroid carcinoma, hyperthyroidism, and cardiac dysfunction.

CONDITIONS

- 10. Licensed material shall be used only at Central Montana Hospital, 408 Wendell Avenue, Lewistown, Montana.
- 11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
25-18307-01

Docket or Reference number
030-14819

Amendment No. 04

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Wiley R. Bland, M.D.

Groups I, II, and III
Iodine-131 as iodide for treatment of
hyperthyroidism, cardiac dysfunction,
and thyroid carcinoma
In vitro studies

Calvin H. Agnew, M.D.

Groups I, II, and III
Iodine-131 for treatment of
hyperthyroidism and cardiac
dysfunction
In vitro studies

Jon A. Anderson, M.D.

Groups I, II, and III
Iodine-131 as iodide for treatment of
hyperthyroidism and cardiac
dysfunction

E. Stewart Taylor, M.D.

Groups I, II, and III
Iodine-131 as iodide for treatment of
hyperthyroidism and cardiac
dysfunction
In vitro studies

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.
14. Patients containing iodine-131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.
15. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:
- A. Has the prior written permission of the hospital's administrator and its Radiation Safety Committee, and

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
25-18307-01

Docket or Reference number
030-14819

Amendment No. 04

15. (continued)

- B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and
- C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above. These records shall be maintained for 5 years from the time the licensee grants its permission under Subitem A above.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

- A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.
- B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.
- C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated October 14, 1983; and letters dated March 30, 1984, and August 9, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Original Signed By
Jack E. Whitten

Date AUG 30 1985

By _____
Nuclear Materials Safety Section
Region IV
Arlington, Texas 76011

Official Record Copy

11 ML40



UNITED STATES

NUCLEAR REGULATORY COMMISSION

REGION IV

611 RYAN PLAZA DRIVE, SUITE 1000
ARLINGTON, TEXAS 76011

SEP 3 1985

BETWEEN: William O. Miller, Chief
License Fee Management Branch
Office of Administration

R. J. Everett, Chief
Material Radiation Protection Section, TPB,
DV&TP, RIV

Verbal OK
8/23

LICENSEE FEE TRANSMITTAL

A. REGION IV

1. APPLICATION ATTACHED

Applicant/Licensee:

Central Montana Hosp.

Application Dated:

August 9, 1985

Control No.:

460732

License No.:

25-18307-01 (030-14819)

2. FEE ATTACHED

Amount:

\$120

Check No.:

15787

3. COMMENTS

Signed

Laura Hurley

Date

August 15, 1985

02120

B. LICENSEE FEE MANAGEMENT BRANCH

1. Fee Category and Amount:

7C - \$120

4/89

2. Correct Fee Paid. Application may be processed for:

Amendment ☒

Renewal ☐

License ☐

Signed

Rita Jacques

Date

8/23/85